Challenge to ABO blood type barrier in living donor liver transplantation

ABO incompatible living donor liver transplantation has the potential to expand the donor pool for patients with end stage liver diseases on the expense of challenges to overcome immunological barriers across blood type.There is a profound impact of age on incidence and severity of antibody mediated rejection(AMR).Even children older than 1 year have chances of AMR;children aged 8 years or older have risks of hepatic necrosis similar to adult liver recipients.The mechanism of AMR is based on circulatory disturbances secondary to inflammation and injury of the vascular endothelium caused by an antibody-antigen-complement reaction.The strategy to overcome ABO blood type barrier is based on both pre-transplant desensitization and adequate treatment of this phenomenon.Nowadays,rituximab is the standard means of desensitization but unfortunately an insufficient aid to treat AMR.Because of low incidence(less than 5%in the rituximab era),in practice of AMR only some case reports about the treatment of clinical AMR are available in the literature.Initial experiences revealed that the proteasome inhibitor,bortezomib might be a promising treatment based on its capacity to deplete plasma cell agents.Although ABO blood type barrier has been counteracted in 95%of patients by applying“rituximab-desensitization”,many issues,such as prediction of high-risk patients of infection and AMR and secure treatment strategies for evoked AMR,remain to be resolved.

Prognostic role of the ABO blood types in Chinese patients with curatively resected non-small cell lung cancer:a retrospective analysis of 1601 cases at a single cancer center

Background:A positive association between the ABO blood types and survival has been suggested in several malignancies.The aim of this study was to assess the role of the ABO blood types in predicting the prognosis of Chinese patients with curatively resected non-small cell lung cancer(NSCLC).Methods:We retrospectively analyzed 1601 consecutive Chinese patients who underwent curative surgery for NSCLC between January 1,2005 and December 31,2009.The relationship between the ABO blood types and survival was investigated.In addition,univariate and multivariate analyses were performed.Results:Group 1(patients with the blood type O or B) had significantly prolonged overall survival(OS) compared with group 2(patients with the blood type A or AB),with a median OS of 74.9 months versus 61.5 months[hazard ratio(HR) 0.83;95%confidence interval(CI) 0.72-0.96;P = 0.015].Additionally,group 1 had significantly longer disease-free survival(DFS;HR 0.86;95%CI 0.76-0.98;P = 0.022) and locoregional relapse-free survival(LRFS;HR 0.79;95%CI 0.64-0.98;P = 0.024) than group 2.The association was not significantly modified by other risk factors for NSCLC,including smoking status,pathologic tumor-node-metastasis stage,pT category,pN category,and chemotherapy.Conclusions:There is an association between the ABO blood types and the survival of Chinese patients with resected NSCLC.Patients with the blood type O or B had significantly prolonged OS,DFS,and LRFS compared with those with the blood type A or AB.

ABO blood type is associated with endometrial cancer risk in Chinese women

ABO blood type has been associated with risk of several malignancies. However, results are not consistent. In this population-based case-control study including 1204 incident endometrial cancer cases and 1212 population controls, we examined the association of self-reported serologic blood type with endometrial cancer risk using a logistic regression model. Women with endometrial cancer were more likely to have blood type A. Compared to women with blood type O, the adjusted odds ratios for endometrial cancer were 1.00 [95% confidence interval (CI), 0.79-1.28] for type B, 1.24 (95% CI, 0.90-1.69) for type AB, and 1.50 (95% CI, 1.19-1.90) for type A. A significant dose-response relationship was observed for cancer risk and level of antigen A (P for trend = 0.0003). The positive association of blood type A with cancer risk was observed regardless of menopausal status, body mass index, oral contraceptive use, or family cancer history. Our results suggest that ABO blood type may be involved in the development of endometrial cancer.

ABO blood type, long-standing diabetes, and the risk of pancreatic cancer

AIM: To retrospectively study pancreatic cancer patients with respect to their ABO blood type and diabetes. METHODS: Our analysis included a cohort of 1017 patients with pancreatic ductal cancer diagnosed at our hospital in Tokyo. They were divided into two groups: 114 patients with long-standing type 2 diabetes (DM group, defined as diabetes lasting for at least three years before the diagnosis of pancreatic cancer) and 903 patients without diabetes (non-DM group). Multivariate analysis was performed to identify factors that are associated with long-standing diabetes. The DM group was further divided into three subgroups according to the duration of diabetes (3-5 years, 5.1-14.9 years, and 15 years or more) and univariate analyses were performed. RESULTS: Of the 883 pancreatic cancer patients with serologically assessed ABO blood type, 217 (24.6%) had blood type O. Compared with the non-DM group, the DM group had a higher frequency of blood type B [odds ratio (OR) = 2.61, 95%CI: 1.24-5.47; reference group: blood type A]. Moreover, male (OR = 3.17, 95%CI: 1.67-6.06), older than 70 years of age (OR = 2.19, 95%CI: 1.20-3.98) and presence of a family history of diabetes (OR = 6.21, 95%CI: 3.38-11.36) were associated with long-standing type 2 diabetes. The mean ages were 64.8 ± 9.2 years, 67.1 ± 9.8 years, and 71.7 ± 7.0 years in the subgroups with the duration of diabetes, 3-5 years, 5.1-14.9 years, and 15 years or more, respectively (P = 0.007). A comparison of ABO blood type distribution among the subgroups also showed a significant difference (P = 0.03). CONCLUSION: The association of pancreatic cancer with blood type and duration of diabetes needs to be further examined in prospective studies.

Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma,nasal type:a triple.center study

Background:The prognostic significance of ABO blood type for lymphoma is largely unknown.We evaluated the prognostic role of ABO blood type in patients with extranodal natural killer(NK)/T-cell lymphoma(ENKTL).Methods:We retrospectively analyzed clinical data of 697 patients with newly diagnosed ENKTL from three cancer centers.The prognostic value of ABO blood type was evaluated using Kaplan-Meier curves and Cox proportional hazard models.The prognostic values of the International Prognostic Index(IPI) and the Korean Prognostic Index(KPI)were also evaluated.Results:Compared with patients with blood type O,those with blood type non-O tended to display elevated baseline serum C-reactive protein levels(P=0.038),lower rate of complete remission(P=0.005),shorter progression-free survival(PFS,P<0.001),and shorter overall survival(OS,P=0.001).Patients with blood type O/AB had longer PFS(P<0.001) and OS(P=0.001) compared with those with blood type A/B.Multivariate analysis demonstrated that age >60 years(P<0.001),mass ≥5 cm(P=0.001),stage Ⅲ/Ⅳ(P<0.001),elevated serum lactate dehydrogenase(LDH) levels(P=0.001),and blood type non-O were independent adverse predictors of OS(P=0.001).ABO blood type was found to be superior to both the IPI in discriminating patients with different outcomes in the IPI low-risk group and the KPI in distinguishing between the intermediate-to-low-and high-to-intermediate-risk groups.Conclusions:ABO blood type was an independent predictor of clinical outcome for patients with ENKTL.

Impact of ABO Blood Types on Survival after Pancreatectomy for Pancreatic Cancer

Background/Purpose: A recent genome-wide association study (PanScan) identified significant association between the ABO gene locus and the risk of pancreatic cancer. The aim of this study was to analyze survival of pancreatic cancer patients who underwent surgical resection based on serotype-defined ABO blood types. Methods: In terms of ABO blood types and gemcitabine-based adjuvant therapy, we investigated the survival of 153 patients who underwent pancreatectomy for pancreatic cancer at the Department of Surgery and Oncology,KyushuUniversity(Fukuoka,Japan). Results: Among the four blood type groups, the O serotype group (median survival time (MST): 47.9 months) showed the best prognostic outcome. The A serotype group (MST: 22.5 months) showed the second best prognostic outcome, followed by the AB serotype group (MST: 20.4 months). The B serotype group (MST: 15 months) showed the worst prognostic outcome when considering the MST after the surgical resection. Next, we examined the effect of adjuvant chemotherapy with gemcitabine based on the ABO blood types. The A serotype group showed the greatest improvement in prognosis by adjuvant therapy with gemcitabine after the surgical resection. The other three serotype groups showed no significant differences in the prognostic outcomes between subgroups with and without gemcitabine therapy. Conclusions: The present data suggest the possibility that ABO blood types are prognostic factors for pancreatic cancer patients after surgical treatment and are also predictive factors for the chemosensitivity to gemcitabine of pancreatic cancer patients after pancreatectomy.

质量监测指标在血站实验室ABO血型检测中的应用

目的分析ABO血型检测相关质量监测指标情况及其变化趋势,探讨质量监测指标在血站实验室ABO血型检测过程中的作用。方法以该中心2012—2021年2733642例献血者标本为研究对象,分析2012—2021年ABO血型检测过程中相关质量监测指标,包括特殊血型检出率、标本血型与血液制剂血型不一致率、采血部门血型检测错误率、送检血型与确认结果符合率等,对数据进行整理和分析。结果2012—2021年2733642例献血者特殊血型检出率中位数为0.030%,各年度比较,差异有统计学意义(0.019%~0.051%;χ^(2)=75.612,P<0.01)。标本血型与血液制剂血型不一致率为0.04■,各年度比较,差异有统计学意义(0.00■~0.21■;χ^(2)=15.787,P<0.01),呈递减趋势(χ^(2)=11.178,P<0.01)。采血部门血型检测错误率为0.55?,各年度比较,差异有统计学意义(0.24■~0.77■;χ^(2)=18.247,P<0.05),呈递减趋势(χ^(2)=8.143,P<0.01)。送检血型与确认结果符合率为78.24%,各年度比较,差异无统计学意义(70.94%~84.71%,χ^(2)=11.993,P>0.05),未见明显趋势变化(χ^(2)=0.879,P>0.05)。结论血站实验室应使用质量监测指标对ABO血型检测进行持续监控和过程评价,确保实验室检测能力的有效性、稳定性,为血型检测过程管理持续改进提供数据依据。

447例ABO血型鉴定自动审核不通过原因分析及解决方法的探讨

目的分析477例ABO血型鉴定自动审核不通过的原因及其影响因素,初步建立相应的处理流程。方法依据并参考临床实验室定量检验结果的自动审核(WS/T 616-2018)的行标,制定了我室ABO血型鉴定的自动审核规则。收集2021年1月至2022年12月北京协和医院检验科ABO血型鉴定自动审核不通过的共计477患者的临床资料,分析ABO血型鉴定不通过的原因,结合患者的临床诊断特征,制定相应的处理流程。结果按原因分类:抗原所致为79例,其中抗原减弱或缺失为50例,亚型为29例;抗体所致为398例,其中血清抗体减弱/缺失为305例,冷凝集素(冷抗体)为23例/自身抗体为27例,红细胞同种抗体为43例。按患者所患疾病类型:肿瘤为94例占19.7%;血液病为59例占12.4%;免疫性疾病为43例占9%;内分泌疾病为25例占5.2%;妇科疾病及妊娠为72例占15.1%;其他疾病为184例占38.6%。结论在477例ABO血型鉴定自动审核不通过的原因中,以年龄变化导致的生理变化最为常见;此外不规则抗体、ABO亚型、抗原减弱也可造成此结果。在血型鉴定工作中,应综合考虑患者的情况,针对其原因选择相应辅助实验方法进行鉴定,以提高ABO血型的鉴定准确性,保证临床用血安全。

血清学检测和基因分型在ABO疑难血型鉴定中的性能评价

目的分析血清学检测和基因分型在ABO疑难血型鉴定中的应用。方法对106例ABO疑难血型实施血清学检测(吸收放散试验)等,同时对其实施基因分型检测(荧光定量PCR试验),以基因测序结果为金标准,评估血清学检测和基因分型所得结果与基因测序一致性,比较两种检查方式灵敏度、特异度。结果以基因测序为金标准,血清学检测所得结果一致性为中度,基因分型检测所得结果一致性很好。通过比较血清学检测和基因分型灵敏度、特异度可知,两种检查方式所得特异度、灵敏度差异有统计学意义,基因分型灵敏度、特异度更高(P<0.05)。结论基因分型检测和血清学检测有各自的优缺点,但总体上来说,基因分型检测具有更高的准确性和可靠性,更快速、高效。

ABO血型不相容儿童活体肝移植的临床疗效分析

目的深入探讨儿童ABO血型不相容活体肝移植的临床疗效及预后情况,为该领域的临床实践提供参考。方法回顾性分析2021—2023年期间在新疆医科大学第一附属医院小儿普外科接受活体肝移植手术的22例患儿的资料。其中,ABO血型相同(ABO-identical,ABO-Id)或相容(ABO-compatible,ABO-C)组共16例,ABO血型不相容(ABO-incompatible,ABO-In)组6例。我们比较了这两组患儿的一般资料、肝移植术后指标、并发症发生情况以及生存情况。结果两组在移植月龄、性别、手术史、PELD评分、捐献者年龄、无肝期时长、手术时长、术后住院时长、他克莫司全血谷浓度和血肌酐值等方面进行比较,结果显示差异均无统计学意义(P>0.05)。两组受体的整体累积生存率比较差异无统计学意义(P>0.05)。在术后肺部感染、巨细胞病毒感染、排斥反应以及血管并发症的发生率方面,两组间的差异同样无统计学意义(P>0.05)。结论儿童ABO血型不相容活体肝移植被认为是一种安全有效的治疗方法,不仅可以扩大供肝来源,而且能够有效挽救患儿的生命。

ABO血型与卵巢癌的相关性研究

目的评估ABO血型与卵巢癌的发病、国际妇产科联盟(FIGO)分期及病理分型的关系。方法收集2012年6月至2023年6月期间在陕西中医药大学第二附属医院确诊且经过初次手术的285例卵巢癌患者临床资料,包括年龄、绝经状态、是否合并恶性腹水,FIGO分期、病理类型、血清癌胚抗原125(CA125)、血型等。选取同期300例卵巢良性肿瘤患者作为对照。回顾性分析ABO血型与卵巢癌发病风险、FIGO分期、病理类型等临床指标之间的关系。采用Kolmogorov-Smirnov检验、F检验、χ^(2)检验、Fisher确切概率法进行统计比较。结果285例卵巢癌患者中,A、B、O和AB型分别为83例(29.1%)、95例(33.3%)、72例(25.3%)和35例(12.3%)。300例卵巢良性肿瘤患者中,A、B、O和AB型分别为77例(25.7%)、90例(30.0%)、99例(33.0%)、34例(11.3%)。O型血在良性肿瘤中占比最高,B型血在卵巢癌患者中占比最高。不同血型卵巢癌患者的年龄、FIGO分期、病理分型、绝经状态、CA125比较,差异均无统计学意义(均P>0.05)。logistic回归模型显示,B型血是卵巢癌患者发病的风险因素(OR=3.518,95%CI=1.519~8.146,P<0.05)。ABO血型与卵巢癌的FIGO分期、病理类型无明显相关性(均P>0.05)。结论B型血是卵巢癌患者中较常见的血型,与卵巢癌风险增加有关;ABO血型与卵巢癌的FIGO分期、病理分型无明显关系。

疑似ABO-HDN患儿的溶血三项检测结果及影响因素分析

目的检测疑似ABO新生儿溶血病(ABO-HDN)的溶血三项,并分析ABO-HDN的影响因素。方法回顾性分析2022年1~12月福鼎市医院收治的150例疑似ABO-HDN患儿的临床资料,所有患儿均进行溶血三项检测,收集所有患儿的相关资料,并分别采用单因素分析、多因素Logistic回归模型分析ABO-HDN的影响因素。结果150例疑似样本中108例被确诊为ABO-HDN,其中直接抗球蛋白试验阳性27例(25.00%),血清游离抗体检测阳性45例(41.67%),红细胞抗体释放试验阳性108例(100.00%),组合试验中,血清游离抗体试验联合红细胞抗体释放试验的阳性率最高;单因素分析结果显示,新生儿ABO-HDN与母-婴血型、妊娠次数、出生体质量和送检日龄有关(P<0.05);经多因素Logistic回归分析结果显示,母-婴血型(母亲血型为O型)(OR=2.303)、妊娠次数(≥2次)(OR=2.214)、出生体质量(≥3000 g)(OR=2.065)、送检日龄(1~3 d)(OR=2.090)是患儿发生ABO-HDN的危险因素(P<0.05)。结论溶血三项试验是ABO-HDN特异性诊断方法,及早检测有利于提高诊断准确率。母亲妊娠次数超过2次、母亲血型为O型、出生体质量高于3000 g、送检日龄1~3 d是ABO-HDN发生的危险因素。

南通市ABO与Rh血型分布特征及人口迁移对其影响

目的 调查分析南通市ABO和恒河猴(Rh)血型的分布特征,探讨区域划分及人口迁移对血型分布的影响。方法 收集南通市1998年1月至2022年12月482 981名献血者数据,以南通市语言地理学特征分为如海片、崇通片和启海片3个地域,统计分析不同区域内ABO及Rh血型分布特征。结果 南通市ABO血型分布特征为O>A>B>AB,Rh阴性占比为0.45%。南通市ABO血型分布有明显的地域差异(χ^(2)=507.953,P<0.001),如海片为A>O>B>AB,崇通片和启海片为O>A>B>AB。结论 南通市ABO血型总体分布特征为O>A>B>AB,血型分布存在地域差异,如海片血型分布为A>O>B>AB,有其特殊性。人口迁移是影响血型分布的重要因素。

血液检测指标与ABO血型不合新生儿溶血病的关系及诊断价值

目的 分析血液检测指标与ABO血型不合新生儿溶血病的关系及诊断价值。方法 收集2021年1月—2022年12月在德江县人民医院分娩的70例新生儿的临床资料。对新生儿静脉血进行红细胞抗体放散实验,通过洗涤、放散、离心,采用全自动血细胞分析仪分析产妇及新生儿的血液检测指标[包括总胆红素(TBil)、中性粒细胞比例(NEU%)、血红蛋白(Hb)、血小板计数(PLT)、直接胆红素(DBil)、平均红细胞体积(MCV)];比较ABO血型不合新生儿溶血病的诊断率以及患儿与正常新生儿的上述指标水平差异。结果 ABO血型不合新生儿溶血病的诊断率为8.57%(6/70);患儿的TBil和NEU%水平均显著高于正常新生儿,Hb水平显著低于正常新生儿[TBil(μmol/L):265.34±16.35比186.34±13.68;NEU%:(65.34±6.37)%比(53.62±5.69)%;Hb(g/L):133.67±16.62比175.65±20.68;均P<0.05];PLT、DBil、MCV与正常新生儿比较差异均无统计学意义[PLT(×10^(9)/L):265.62±18.62比265.37±18.67;DBil(μmol/L):19.32±4.32比18.99±3.96;MCV(fL):104.32±6.34比104.37±6.38;均P>0.05]。结论 血液检测中Hb、NEU%、MCV、TBil等指标与新生儿溶血病的患病情况有关,可作为疾病早期预测和诊断的重要依据。上述指标联合检测可进一步提高诊断的准确性,为临床及时治疗和干预提供有力支持。

徐州地区380例ABO正反定型不符的回顾性分析

目的探讨徐州地区380例ABO正反定型不符的原因。方法整理2011年1月至2022年12月徐州市红十字血液中心输血研究科实验室为ABO正反定型不符的实验记录,通过分析受检者临床资料及ABO血型检测情况,对导致ABO正反定型不符的原因进行分类总结。结果共380例ABO正反定型不符记录,主要的原因包括自身抗体干扰151(39.74%)例,意外抗体干扰77(20.26%)例,ABO亚型77(20.26%)例,疾病导致的抗原减弱27(7.11%)例,蛋白凝集干扰19(5.00%)例;151例自身抗体干扰ABO正反定型中,导致额外抗原反应38(25.17%)例,导致额外抗体反应69(45.70%)例,导致额外的抗原反应和额外的抗体反应44例(29.14%);77例意外抗体干扰ABO正反定型中,MNS血型系统抗体42(54.55%)例,Rh血型系统抗体15(19.48%)例,P1Pk血型系统抗体3(3.90%)例,Lewis血型系统抗体1(1.30%)例,特异性不明的意外抗体16(20.80%)例。结论导致本地区ABO正反定型不符主要原因为自身抗体干扰、意外抗体干扰、ABO亚型,其中自身抗体能导致ABO正反定型不符表现出不同的类型,检测时要加以鉴别,保证ABO血型鉴定的准确性。

The correlation between different ABO blood group gene loci and the pathogenesis and prognosis of acute myocardial infarction

Objective: To assess the effect of different ABO blood group gene locus on severity and prognosis of acute myocardial infarction (AMI). Methods: 100 patients with AMI diagnosed in our hospital from June 2018 to June 2019 were selected as the myocardial infarction group. At the same time, 100 healthy patients with physical examination results in our hospital were selected as the control group. Single-nucleotide polymorphisms of peripheral blood ABO gene loci rs505922, rs579459, rs643434, rs651007, and rs8176743 were detected. The differences of ABO blood group gene loci in different groups were compared. The correlation between the distribution of ABO blood group gene loci and the incidence and prognosis of patients with AMI was analyzed. Results: 98 cases were included in the myocardial infarction group and 99 cases were included in the control group. Compared with the control group, the genotypes of rs643434 and rs651007 locus in the myocardial infarction group were statistically significant (P<0.05). Analysis under different genetic models , compared with the control group, the myocardial infarction group had a significant difference in the rs643434 gene dominant mode, rs651007 dominant mode and recessive mode (P<0.05). The dominant mode of rs643434 was correlated with Gensini score and TIMI grade. The dominant mode of rs651007 was correlated with Gensini score, TIMI grade and troponin.The recessive mode of rs651007 was correlated with Gensini score, and the differences were statistically significant (P < 0.05). The dominant mode of rs643434 was related to the occurrence of MACE, and the difference was statistically significant (P < 0.05).Conclusion: Different genetic models of ABO blood group genes rs643434 and rs651007 may be related to the condition and prognosis of AMI.

广东潮汕地区恶性肿瘤与ABO血型的相关性分析

目的探讨ABO血型与广东潮汕地区恶性肿瘤发病风险的关系。方法采用卡方检验分析汕头大学医学院附属肿瘤医院45890例恶性肿瘤患者和汕头市中心血站42465例健康献血者中ABO血型分布差异。结果在各种主要类型恶性肿瘤中,食管癌和头颈部癌的ABO血型分布与正常人群分布存在差异,具有统计学意义(χ^(2)=11.16,P<0.05;χ^(2)=74.36,P<0.05)。B型人群为食管癌和头颈部癌高风险人群(OR=1.09,95%CI=1.03~1.15,P<0.05;OR=1.46,95%CI=1.34~1.60,P<0.05);A型和O型人群是头颈部癌低风险人群(OR=0.87,95%CI=0.79~0.96,P<0.05;OR=0.83,95%CI=0.76~0.90,P<0.05)。结论潮汕地区汉族人食管癌和头颈部癌患者ABO血型分布与正常人群可能存在差异,提示不同血型可能与食管癌和头颈部癌的发生存在关联。

江苏省启东地区肝癌患者ABO血型分布及其与肝癌发病风险的关系

目的了解江苏省启东地区肝癌患者ABO血型分布情况,探讨ABO血型与肝癌发病风险的关系。方法选择1701例启东籍肝癌患者、2828例排除疾病后的启东籍健康体检人员,采集两组外周静脉血检测ABO血型,分析ABO血型与肝癌发生风险的关系。结果1701例肝癌患者中,血型为A型者518例(30.45%)、B型者436例(25.63%)、O型者518例(30.45%)、AB型者229例(13.46%);2828例体检健康者中,血型为A型者862例(30.48%)、B型者818例(28.93%)、O型者853例(30.16%)、AB型者295例(10.43%),与健康人群比较,肝癌患者中AB型比例高、B型比例低(P均<0.05)。B型的启东籍人群发生肝癌的风险低(OR=0.847,95%CI:0.739~0.970),AB型启东籍人群发生肝癌的风险高(OR=1.336,95%CI 1.111~1.606)。与健康人群比较,男性肝癌患者B型比例低、AB型比例高(χ^(2)=5.618,11.01;OR分别为0.809,1.534;P均<0.05)。结论江苏省启东地区肝癌的发生与ABO血型有关,AB型人群发生肝癌的风险高,B型人群发生肝癌的风险低。

精准ABO血型鉴定与精准输血的价值研究

目的:研究精准ABO血型鉴定与精准输血的价值。方法:选取2017年11月—2019年10月新郑市人民医院需进行输血的患者132例,按照随机数表法分为试验组(n=66)与对照组(n=66),对照组采用常规ABO血型鉴定,试验组采用精准ABO血型鉴定。分析ABO血型在不同年龄段及不同性别分布特点,比较两组患者不规则抗体阳性与D抗体阳性率。结果:132例需输血患者中,A型血31例,占比23.48%(31/132),B型血28例,占比21.21%(28/132),O型血53例,占比40.15%(53/132),AB型血20例,占比15.15%(20/132);其中20~39岁、40~59岁、≥60岁年龄段中血型分布均为AB型<B型<A型<O型;医院132例需输血患者中,男性A型血、B型血、O型血、AB型血分别为17例(12.88%)、15例(11.36%)、28例(21.21%)、11例(8.33%),女性A型血、B型血、O型血、AB型血分别为14例(10.61%)、13例(9.85%)、25例(18.94%)、9例(6.82%),男性与女性血型分布均为AB型<B型<A型<O型;与对照组[12.12%(8/66)、13.64%(9/66)]相比,试验组不规则抗体阳性率[3.03%(2/66)]、D抗体阳性率[1.52%(1/66)]均较低,差异有统计学意义(χ^(2)=3.895、6.925,P<0.05)。结论:ABO血型在不同年龄段及性别中分布不同,对患者进行精准ABO血型鉴定可为临床精准输血提供依据,有助于临床匹配血型。

ABO疑难血型鉴定及正反定型不符原因分析

目的:分析ABO疑难血型鉴定及正反定型不符原因。方法:选取2021年1月—2023年5月厦门大学附属第一医院杏林分院92例ABO疑难血型血液标本。所有血液标本采用盐水试管法进行血型正反定型,并采用凝聚胺法、吸收放散试验对血型进行进一步检测。统计三种方法检测血型正反定型的符合率,并分析盐水试管法正反定型不符合的原因,完成ABO血型鉴定。结果:92例血液标本检测结果显示,盐水试管法、盐水试管法+凝聚胺法、盐水试管法+凝聚胺法+吸收放散试验检测血型正反定型符合率分别为44.57%(41/92)、51.09%(47/92)、77.17%(71/92)。盐水试管法正反定型不符合的主要原因为AB亚型、弱B抗原、弱A抗原、无抗-B抗体A型、无抗体O型。92例ABO疑难血型中,A亚型29例,B亚型50例,AB亚型13例。结论:临床通过盐水试管法+凝聚胺法+吸收放散试验对ABO疑难血型进行正反定型,可提高血型鉴定准确率。